Company Announcements

Diaceutics PLC - Board Changes

Belfast and London, 23 July 2024 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, today announces the following changes to its board.

Deborah Davis has today informed the board after three and a half years' service as Non-Executive Chair of Diaceutics, of her intention to step down from the board effective 1 October 2024.

Peter Keeling, a co-founder and Executive Director of Diaceutics will succeed Deborah as Non-Executive Chair effective 1 October 2024. Peter will also serve as a Non-Executive Director on the Remuneration and Audit & Risk Committees.

Deborah Davis, Non-Executive Chair of Diaceutics commented: "With a mixture of pride and gratitude, I announce my decision to step down as Chair of Diaceutics. During my tenure, our collective efforts have scaled the Company and transformed its business model, delivering significant growth and positioning Diaceutics as a key commercialisation partner to pharma and biotech companies in their quest to find patients that benefit from their precision medicines. I extend my deepest gratitude to our board, executive team, employees, partners, and shareholders for their unwavering support. Under Peter's stewardship, I am confident the Company will continue to grow and succeed."

Ryan Keeling, Chief Executive Officer of Diaceutics commented: "I would like to thank Deborah for her tireless dedication and efforts in guiding Diaceutics through a crucial stage in our development and growth as a public company. We will miss her presence and wish her well for her current and future roles. I look forward to working closely with the board and continuing my close partnership with Peter in his new capacity as Chair."

Enquiries: 

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.

We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network ®.